







Example 201		6-(4-fluorophenyl)-8-{[(3R)-oxolan-3-yl]oxy}-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}quinazolin-4-amine ~~(R)-4-(2-(1,1-dioxidothiomorpholino)ethyl)-8-(4-fluorophenyl)-3-oxo-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide~~
Example 202		6-(4-fluorophenyl)-8-isopropoxy-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine
Example 203		8-(cyclopropylmethoxy)-6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine
Example 204		2-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxyethanol
Example 205		2-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxy-N,N-dimethyl-acetamide
Example 206		6-(4-fluorophenyl)-8-(2-methoxyethoxy)-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine
Example 207		6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-(oxetan-3-ylmethoxy)quinazolin-4-amine




Nitrogen was bubbled for 5 min through a mixture of (*R*)-6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-ol (40 mg, 0.01 mmol), tetrahydro-4-pyranol (10 mg, 0.102 mmol) and cyanomethyltributylphosphorane (1 M in toluene, 0.14 mL, 0.14 mmol) in toluene (3.0 mL). The mixture was heated to 100 °C for 72 hours. After return to room temperature, the solvent was removed *in vacuo.* The residue was purified by preparative HPLC to give the title compound (17 mg, 38%) as an off white solid.

^{1}H NMR (400 MHz, DMSO): δ 9.18 (s, 2 H), 8.64 (d, J = 7.0 Hz, 1 H), 8.44 (s, 1 H), 8.23 (d, J = 1.6 Hz, 1 H), 7.94-7.89 (m, 2 H), 7.65 (d, J = 1.6 Hz, 1 H), 7.39 (dd, J = 8.8, 8.8 Hz, 2 H), 5.71-5.66 (m, 1 H) 5.02-4.94 (m, 1 H), 3.96-3.88 (m, 2 H), 3.51 (dd, J = 9.7, 9.7 Hz, 2 H), 2.07-2.00 (m, 2 H), 1.74 (d, J = 7.0 Hz, 5 H). LCMS (Method 3): [MH+] = 514 at 3.79 min.

Example 201

6-(4-fluorophenyl)-8-{[(3R)-oxolan-3-yl]oxy}-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}quinazolin-4-amine

~~**(R)-4-(2-(1,1-dioxidothiomorpholino)ethyl)-8-(4-fluorophenyl)-3-oxo-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide**~~




Potassium carbonate (47.7 mg, 0.345 mmol) was added to a mixture of (R)-6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-ol

NaOH (10.5 mg, 0.26 mmol) was added to ethyl 2-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxyacetate (117 mg, 0.26 mmol) (Example 211) in MeOH (2.2 mL). The mixture was stirred at rt for 3 days then diluted with diethyl ether and filtered to leave 2-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxyacetic acid sodium salt (87 mg, 75 % yield) as a white powder.

Example 215

8-(azetidin-3-ylmethoxy)-6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine




Cesium carbonate (360 mg, 1.1 mmol) was added to a mixture of Example 186A (200 mg, 0.55 mmol) and N-Boc-3-(Iodomethyl)azetidine (247 mg, 0.72 mmol) in DMF (Volume: 3 ml). Stirring went on at 25 °C for 48 h. The crude material was ~~purifies~~ purified by chromatography. The intermediate Boc-protected amine (150 mg, 0.28 mmol) was treated with 8N HCl in MeOH at RT for 3 days to leave 8-(azetidin-3-ylmethoxy)-6-(4-fluorophenyl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine (122 mg, 87 % yield) as a white powder.

LCMS (Method 7):: 2.24 min, [M+H]+ 431.1Se1 6min

^{1}H NMR (300 MHz, METHANOL-d4) δ ppm 8.80 (s, 1 H), 8.49 (d, J=8.80 Hz, 1 H), 8.37 (d, J=1.28 Hz, 1 H), 8.31 (br d, J=8.44 Hz, 1 H), 7.90 - 7.97 (m, 3 H), 7.33 (t, J=8.71 Hz, 2 H), 5.43 (s, 2 H), 4.60 (d, J=4.95 Hz, 2 H), 4.34 (dd, J=8.44, 3.48 Hz, 4 H), 2.89 (s, 3 H)

CLAIMS

1. A compound of formula (I)



(I)

wherein

Z is selected from the group consisting of (C_3-C_8)heterocycloalkyl, (R^AR^B)N-, heteroaryl, aryl,

wherein any of such ~~alkyl,~~ heteroaryl, heterocycloalkyl and aryl may be optionally substituted by one or more groups selected from (C_1-C_3)alkyl-, halo, CN, (R^AR^B)NC(O)-, (C_1-C_6)haloalkyl-, R^AO-, (R^AR^B)N(C_1-C_6)alkylene-, (C_3-C_7)cycloalkyl-, R^CSO_2-, (R^AR^B)N-;

R_1 is H or (C_1-C_4)alkyl;

R_2 is selected from the group consisting of (C_1-C_6)alkyl-, heteroaryl(C_1-C_4)alkyl-, (C_3-C_8)heterocycloalkyl-(C_1-C_6)alkyl-, heteroaryl-(C_1-C_6)hydroxyalkyl-, (C_3-C_8)heterocycloalkyl, (C_3-C_8)cycloalkyl-(C_1-C_6)alkyl-, aryl-(C_1-C_4)alkyl-, (R^AR^B)N(C_1-C_6)alkylene-, (R^AR^B)N(O)C(C_1-C_4)alkylene- and R^AO(C_1-C_4)alkylene-,

wherein any of such alkyl, alkylene, aryl, heteroaryl and heterocycloalkyl may be optionally substituted by one or more groups selected from (C_1-C_3)alkyl, R^AO(C_1-

C_4)alkylene-, (C_1-C_6)haloalkyl, halo, oxo, R^AO-, (C_3-C_8)heterocycloalkyl-(C_1-C_6)alkyl-, heteroaryl, (R^AR^B)N-, -NHC(O)R^C, -C(O)N(R^AR^B), -SO_2N(R^AR^B), -O(C_1-C_4)alkylene-N(R^AR^B), aryl optionally substituted by halo, -OR^C, aryl-(C_1-C_4)alkyl-, -C(O)R^A;

R^A and R^B are at each occurrence independently H or selected from the group consisting of (C_1-C_4)alkyl-, (C_3-C_8)cycloalkyl-, (C_1-C_6) haloalkyl, or

R^A and R^B may form together with the nitrogen atom to which they are attached a 5 or 6 membered saturated heterocyclic monocyclic ring system optionally containing a further heteroatom which is nitrogen or oxygen, which may be optionally substituted by one or more groups selected from (C_1-C_4)alkyl and oxo;

R^C is at each occurrence H or selected from the group consisting of (C_1-C_6)alkyl, (R^AR^B)N-, aryl-(C_1-C_4)alkyl-;

Y is selected from the group consisting of ~~H,~~ -OR^D, R^CSO_2, halo, -$NHSO_2R^C$, heteroaryl~~,~~ and (C_3-C_8)heterocycloalkyl,

wherein any of such heteroaryl and heterocycloalkyl may be optionally substituted by one or more groups selected from (C_1-C_3)alkyl~~,~~ and -C(O)N(R^AR^B);

R^D is selected from the group consisting of H, (C_1-C_6)alkyl, (C_3-C_8)heterocycloalkyl-(C_1-C_6)alkyl-, $R^COC(O)$(C_1-C_4)alkylene-, (R^AR^B)N(C_1-C_6)alkylene-, (C_3-C_8)heterocycloalkyl, (C_3-C_8)cycloalkyl-(C_1-C_6)alkyl-, R^CO(C1-C4)alkylene-, (R^AR^B)N(O)C(C_1-C_4)alkylene-,

wherein any of such heterocycloalkyl may be optionally substituted by one or more groups selected from (C_1-C_3)alkyl-;

J is H or selected from the group consisting of (C_1-C_6)alkyl, (R^AR^B)N-, (C_1-C_6)haloalkyl, -OR^C and halo.

2. A compound ~~of formula I according to claim 1 selected~~ selected from the group consisting of:

(R)-6-(4-Fluorophenyl)-8-methoxy-N-(1-(6-methylpyridazin-3-yl)ethyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((2-(trifluoromethyl)pyrimidin-5-yl)methyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-(2-(6-methylpyridin-3-yl)ethyl)quinazolin-4-amine,

N-([1,2,4]Triazolo[4,3-a]pyrimidin-3-ylmethyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine,

6-[[[6-(4-Fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]methyl]-1H-pyridin-2-one,

6-(4-Fluorophenyl)-8-methoxy-N-[(1-methyl-4-piperidyl)methyl]quinazolin-4-amine,

(R)-5-(1-((6-(4-fluorophenyl)-8-methoxyquinazolin-4-yl)amino)ethyl)-2-(trifluoromethyl)pyridine 1-oxide formate,

8-Methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(5-methylpyridin-2-yl)quinazolin-4-amine,

8-Methoxy-N-[(6-methylpyridazin-3-yl)methyl]-6-(5-methylpyrimidin-2-yl)quinazolin-4-amine,

8-Methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(5-methylthiazol-2-yl)quinazolin-4-amine,

(R)-5-(1-((8-Methoxy-6-(5-methyl-1,3,4-thiadiazol-2-yl)quinazolin-4-yl)amino)ethyl)-2-(trifluoromethyl)pyridine 1-oxide,

8-Methoxy-6-(5-methylpyrimidin-2-yl)-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]quinazolin-4-amine,

6-(5-Fluoropyrimidin-2-yl)-8-methoxy-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]quinazolin-4-amine,

6-(5-Fluoro-2-pyridyl)-8-methoxy-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]quinazolin-4-amine,

8-Methoxy-N-[(1R)-1-(6-methylpyridazin-3-yl)ethyl]-6-(5-methylpyrimidin-2-yl)quinazolin-4-amine,

8-Methoxy-6-(1-methylpyrazol-3-yl)-N-[(1R)-1-(6-methylpyridazin-3-yl)ethyl]quinazolin-4-amine,

6-(5-Fluoro-2-pyridyl)-8-methoxy-N-[(1R)-1-(6-methylpyridazin-3-yl)ethyl]quinazolin-4-amine,

6-(5-Chloropyridin-2-yl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

(R)-6-(4-fluorophenyl)-8-methoxy-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

6-(4-fluorophenyl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

(R)-6-(4-Fluorophenyl)-8-methoxy-4-((1-(2-(trifluoromethyl)pyrimidin-5yl)ethyl)-amino)-quinazolin-2-ol,

6-(4-fluorophenyl)-8-(2-methoxyethoxy)-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-(oxetan-3-ylmethoxy)quinazolin-4-amine,

6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-tetrahydropyran-4-yloxy-quinazolin-4-amine,

2-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxyacetic acid, sodium salt,

6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-pyrrolidin-3-yloxy-quinazolin-4-amine,

6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-(morpholin-2-ylmethoxy)quinazolin-4-amine,

6-(5-methylpyridin-2-yl)-N-((6-methylpyridin-3-yl)methyl)quinazolin-4-amine,

N-((6-methylpyridazin-3-yl)methyl)-6-(5-methylpyridin-2-yl)quinazolin-4-amine,

N-((6-methylpyridin-3-yl)methyl)-6-(5-methylthiophen-2-yl)quinazolin-4-amine,

N-((6-methylpyridin-3-yl)methyl)-6-(p-tolyl)quinazolin-4-amine,

(R)-6-(4-fluorophenyl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

6-(4-fluorophenyl)-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine,

6-(4-fluorophenyl)-N-((6-methylpyridin-3-yl)methyl)quinazolin-4-amine formate,

Single enantiomer 1 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine

Single enantiomer 2 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine,

Single enantiomer 1 of 2-((6-(4-fluorophenyl)-8-methoxyquinazolin-4-yl)amino)-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethan-1-ol,

Single enantiomer 2 of 2-((6-(4-fluorophenyl)-8-methoxyquinazolin-4-yl)amino)-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethan-1-ol,

Single enantiomer 1 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(5-methyl-1,3,4-thiadiazol-2-yl)ethyl)quinazolin-4-amine,

Single enantiomer 2 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(5-methyl-1,3,4-thiadiazol-2-yl)ethyl)quinazolin-4-amine,

Single enantiomer 1 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine,

Single enantiomer 2 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine,

6-(3,5-Difluoropyridin-2-yl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

6-(3-Fluoro-5-methyl-2-pyridyl)-8-methoxy-*N*-[(6-methylpyridazin-3-yl)methyl] quinazolin-4-amine,

6-(5-Ethylthiazol-2-yl)-8-methoxy-*N*-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

(R)-8-methoxy-6-(1-methyl-1H-1,2,4-triazol-3-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

(R)-8-methoxy-6-(1-methyl-1H-pyrazol-3-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

(R)-8-methoxy-6-(1-methyl-1H-1,2,4-triazol-3-yl)-N-(1-(6-methylpyridazin-3-yl)ethyl)quinazolin-4-amine,

(R)-6-(5-fluoropyridin-2-yl)-8-methoxy-N-(1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)quinazolin-4-amine,

(R)-8-methoxy-N-(1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)-6-(5-methylpyridin-2-yl)quinazolin-4-amine,

8-Methoxy-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-6-(5-methyl-2-pyridyl)quinazolin-4-amine,

6-(5-fluoro-2-pyridyl)-8-methoxy-N-[(1R)-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]quinazolin-4-amine,

8-methoxy-N-[(1R)-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-(5-methyl-2-pyridyl)quinazolin-4-amine,

6-(5-fluoro-2-pyridyl)-8-methoxy-N-[1-[6-(trifluoromethyl)pyridazin-3-yl]ethyl]quinazolin-4-amine,

6-(5-fluoropyridin-2-yl)-8-methoxy-N-(1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl)quinazolin-4-amine,


6-(5-fluoropyridin-2-yl)-8-methoxy-N-(1-(5-methyl-1,3,4-thiadiazol-2-yl)ethyl)quinazolin-4-amine,

8-methoxy-N-[(1R)-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-(5-methylpyrimidin-2-yl)quinazolin-4-amine,

(S)-6-(5-fluoropyridin-2-yl)-8-methoxy-N-(1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)quinazolin-4-amine~~,~~ and

8-Methoxy-N-[(1S)-1-(6-methylpyridazin-3-yl)ethyl]-6-(5-methylpyrimidin-2-yl)quinazolin-4-amine.

3. A compound of formula I according to claim 1,



(I)

wherein

Z is selected from the group consisting of heteroaryl, aryl, $(R^AR^B)N$, (C_3-C_8)heterocycloalkyl,

wherein any of such heteroaryl, aryl and heterocycloalkyl may be optionally substituted by one or more groups selected from (C_1-C_3)alkyl, halo, CN, $(R^AR^B)NC(O)$;

R_1 is H or (C_1-C_4)alkyl;

R_2 is selected from the group consisting of heteroaryl(C1-C4)alkyl, $(R^AR^B)N(O)C(C_1-C_4)$alkylene,

wherein any of such heteroaryl may be optionally substituted by one or more groups selected from (C_1-C_3)alkyl, halo, (C_1-C_6) haloalkyl;

R^A and R^B are at each occurrence independently H, (C_1-C_4)alkyl and (C_3-C_8)cycloalkyl, or R^A and R^B may form together with the nitrogen atom to which they are attached a 5 or 6 membered saturated heterocyclic monocyclic ring

~~system optionally containing a further heteroatom which is oxygen or nitrogen, which may be optionally substituted by one or more groups selected from oxo, (C_1-C_4)alkyl;~~

~~**Y** is H;~~

~~**J** is H or selected from the group consisting of (C_1-C_4)alkyl, (R^AR^B)N-, halo, (C_1-C_6)haloalkyl.~~

43. A compound ~~of formula I according to claim 2 selected~~ selected from the group consisting of:

6-(5-methylpyridin-2-yl)-N-((6-methylpyridin-3-yl)methyl)quinazolin-4-amine,

N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)-6-(5-methylpyridin-2-yl)quinazolin-4-amine,

N-((6-methylpyridazin-3-yl)methyl)-6-(5-methylpyridin-2-yl)-2-(trifluoromethyl)quinazolin-4-amine,

N-((6-methylpyridazin-3-yl)methyl)-6-(5-methylpyridin-2-yl)quinazolin-4-amine,

N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)-6-(5-methylthiazol-2-yl)quinazolin-4-amine,

2-chloro-6-(4-fluorophenyl)-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine,

N2-cyclopropyl-6-(4-fluorophenyl)-N4-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)quinazoline-2,4-diamine,

6-(4-fluorophenyl)-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)-2-morpholinoquinazolin-4-amine,

2-((2-(cyclopropylamino)-6-(4-fluorophenyl)quinazolin-4-yl)amino)propanamide,

N-cyclopropyl-2-((2-(cyclopropylamino)-6-(4-fluorophenyl)quinazolin-4-yl)amino)propanamide,

6-(4-fluorophenyl)-2-methyl-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

N-((6-methylpyridin-3-yl)methyl)-6-(5-methylthiophen-2-yl)quinazolin-4-amine,

N-((6-methylpyridin-3-yl)methyl)-6-(p-tolyl)quinazolin-4-amine,

N-((6-methylpyridazin-3-yl)methyl)-6-(2-methylpyrimidin-5-yl)quinazolin-4-amine,

(R)-6-(4-fluorophenyl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

6-(4-fluorophenyl)-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine,

2-(4-(((6-methylpyridin-3-yl)methyl)amino)quinazolin-6-yl)benzonitrile,

2-(4-(((6-methylpyridin-3-yl)methyl)amino)quinazolin-6-yl)benzamide,

6-(4-fluorophenyl)-N-((6-methylpyridin-3-yl)methyl)quinazolin-4-amine formate,

6-(4-fluorophenyl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

N-((3,5-difluoropyridin-2-yl)methyl)-6-(4-fluorophenyl)quinazolin-4-amine hydrochloride,

6-(4-fluorophenyl)-N-methyl-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl) quinazolin-4-amine,

(R)-6-(3,3 difluoropyrrolidin-1-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

(R)-6-morpholino-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

(R)-1-methyl-4-(4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino) quinazolin-6-yl)piperazin-2-one,

N-((6-methylpyridazin-3-yl)methyl)-6-morpholinoquinazolin-4-amine,

Single enantiomer 1 of 6-(4-fluorophenyl)-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]quinazolin-4-amine,

Single enantiomer 2 of 6-(4-fluorophenyl)-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]quinazolin-4-amine,

Single enantiomer 1 of N2-cyclopropyl-6-(4-fluorophenyl)-N4-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]quinazoline-2,4-diamine,

Single enantiomer 2 of N2-cyclopropyl-6-(4-fluorophenyl)-N4-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]quinazoline-2,4-diamine,


Single enantiomer 1 of 6-(4-fluorophenyl)-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-2-morpholino-quinazolin-4-amine,

Single enantiomer 2 of 6-(4-fluorophenyl)-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-2-morpholino-quinazolin-4-amine,

Single enantiomer 1 of 6-(4-fluorophenyl)-N2,N2-dimethyl-N4-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]quinazoline-2,4-diamine, and

Single enantiomer 2 of 6-(4-fluorophenyl)-N2,N2-dimethyl-N4-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]quinazoline-2,4-diamine.

~~54~~. A compound of formula I according to claim 1,



(I)

wherein

Z is selected from the group consisting of heteroaryl and aryl,

wherein any of such heteroaryl and aryl may be optionally substituted by one or more groups selected from $(C_1\text{-}C_3)$alkyl, halo, CN, $(R^AR^B)NC(O)$-, ————$(C_1\text{-}C_6)$haloalkyl, R^AO-, $(R^AR^B)N(C_1\text{-}C_6)$alkylene-, $(C_3\text{-}C_7)$cycloalkyl-, R^CSO_2-, $(R^AR^B)N$-;

R_1 is H or $(C_1\text{-}C_4)$alkyl,

R_2 is selected from the group consisting of $(C_1\text{-}C_6)$alkyl, heteroaryl$(C_1\text{-}C_4)$alkyl-, $(C_3\text{-}C_8)$heterocycloalkyl-$(C_1\text{-}C_6)$alkyl, heteroaryl-$(C_1\text{-}C_6)$hydroxyalkyl, aryl-$(C_1\text{-}C_4)$alkyl-, $(C_3\text{-}C_8)$heterocycloalkyl, $(C_3\text{-}C_8)$cycloalkyl-$(C_1\text{-}C_6)$alkyl-, $(R^AR^B)N(C_1\text{-}C_6)$alkylene-; $R^AO(C_1\text{-}C_4)$alkylene,

wherein any of such alkyl, alkylene, aryl, heteroaryl, cycloalkyl and heterocycloalkyl may be optionally substituted by one or more groups selected from

$(C_1\text{-}C_3)$alkyl, $R^AO(C_1\text{-}C_4)$alkylene, $(C_1\text{-}C_6)$haloalkyl, oxo, R^AO-, $(C_3\text{-}C_8)$heterocycloalkyl-$(C_1\text{-}C_6)$alkyl, heteroaryl, aryl optionally substituted by halo, R^CO-, $(R^AR^B)N$-, -$NHC(O)R^C$, -$C(O)N(R^AR^B)$, halo, -$SO_2N(R^AR^B)$, -$O(R^AO(C_1\text{-}C_4)$alkylene-$N(R^AR^B)$, aryl-$(C_1\text{-}C_4)$alkyl-, -$C(O)R^A$,

R^A and R^B are at each occurrence independently H or selected from the group consisting of $(C_1\text{-}C_4)$alkyl-, ~~aryl,~~ $(C_1\text{-}C_6)$ haloalkyl, or

R^A and R^B may form together with the nitrogen atom to which they are attached a 6 membered saturated heterocyclic monocyclic ring system optionally containing a further heteroatom which is nitrogen or oxygen, which may be optionally substituted by $(C_1\text{-}C_4)$alkyl- and oxo;

R^C is H or selected from the group consisting of $(C_1\text{-}C_6)$alkyl, $(R^AR^B)N$-, aryl-$(C_1\text{-}C_4)$alkyl-,


Y is selected from the group consisting of -OR^D, R^CSO_2-, halo, -$NHSO_2R^C$, heteroaryl, $(C_3\text{-}C_8)$heterocycloalkyl,

wherein any of such heteroaryl and heterocycloalkyl may be optionally substituted by one or more groups selected from $(C_1\text{-}C_3)$alkyl, -$C(O)N(R^AR^B)$;

J is H or selected from the group consisting of $(C_1\text{-}C_6)$alkyl, -OR^C,

R^D is H or $(C_1\text{-}C_6)$alkyl.

~~6~~5. A compound of formula I according to claim 1,



(I)

wherein

Z is selected from the group consisting of heteroaryl and aryl,

wherein any of such heteroaryl and aryl may be optionally substituted by one or more groups selected from $(C_1\text{-}C_3)$alkyl, halo, CN, $(R^AR^B)NC(O)$-, ————$(C_1\text{-}C_6)$haloalkyl, —R^AO-, $(R^AR^B)N(C_1\text{-}C_6)$alkylene-, $(C_3\text{-}C_7)$cycloalkyl-, R^CSO_2-, and $(R^AR^B)N$-;

R_1 is H,

R_2 is selected from the group consisting of $(C_1\text{-}C_6)$alkyl, heteroaryl$(C_1\text{-}C_4)$alkyl-, $(C_3\text{-}C_8)$heterocycloalkyl-$(C_1\text{-}C_6)$alkyl, heteroaryl-$(C_1\text{-}C_6)$hydroxyalkyl, aryl-$(C_1\text{-}C_4)$alkyl-, $(C_3\text{-}C_8)$heterocycloalkyl, $(C_3\text{-}C_8)$cycloalkyl-$(C_1\text{-}C_6)$alkyl-, $(R^AR^B)N(C_1\text{-}C_6)$alkylene-; $R^AO(C_1\text{-}C_4)$alkylene,

wherein any of such alkyl, alkylene, aryl, heteroaryl, cycloalkyl and heterocycloalkyl may be optionally substituted by one or more groups selected from $(C_1\text{-}C_3)$alkyl, $R^AO(C_1\text{-}C_4)$alkylene, $(C_1\text{-}C_6)$haloalkyl, oxo, R^AO-, $(C_3\text{-}C_8)$heterocycloalkyl-$(C_1\text{-}C_6)$alkyl, heteroaryl, aryl optionally substituted by halo, R^CO-, $(R^AR^B)N$-, -$NHC(O)R^C$, -$C(O)N(R^AR^B)$, halo, -$SO_2N(R^AR^B)$, -$O(R^AO(C_1\text{-}C_4)$alkylene-$N(R^AR^B)$, aryl-$(C_1\text{-}C_4)$alkyl-, -$C(O)R^A$,

R^A and R^B are at each occurrence independently H or selected from the group consisting of $(C_1$-$C_4)$alkyl-, ~~aryl,~~ $(C_1$-$C_6)$ haloalkyl, or

R^A and R^B may form together with the nitrogen atom to which they are attached a 6 membered saturated heterocyclic monocyclic ring system optionally containing a further heteroatom which is nitrogen or oxygen, which may be optionally substituted by $(C_1$-$C_4)$alkyl- and oxo;

R^C is H or selected from the group consisting of $(C_1$-$C_6)$alkyl, (R^AR^B)N-, aryl-$(C_1$-$C_4)$alkyl-,

Y is selected from the group consisting of -OR^D, R^CSO_2-, halo, -$NHSO_2R^C$, heteroaryl, $(C_3$-$C_8)$heterocycloalkyl,

wherein any of such heteroaryl and heterocycloalkyl may be optionally substituted by one or more groups selected from $(C_1$-$C_3)$alkyl, -C(O)N(R^AR^B);

J is H or selected from the group consisting of $(C_1$-$C_6)$alkyl, -OR^C,

R^D is H or $(C_1$-$C_6)$alkyl.

~~7~~6. A compound of formula I according to claims ~~4~~ 4 or 5 ~~and 6~~, selected from the group consisting of:

(R)-6-(4-Fluorophenyl)-8-methoxy-2-methyl-N-(1-(2-(trifluoromethyl)pyrimidin-5 yl)ethyl)quinazolin-4-amine,

(R)-6-(4-Fluorophenyl)-8-methoxy-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)-amino)-quinazolin-2-ol-,

(R)-6-(4-Fluorophenyl)-2,8-dimethoxy-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine-,

6-(4-Fluorophenyl)-8-methoxy-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((5-methylpyridin-2-yl)methyl)quinazolin-4-amine,

N-((6-(Difluoromethoxy)pyridin-3-yl)methyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine,

(R)-6-(4-Fluorophenyl)-8-methoxy-N-(1-(6-methylpyridazin-3-yl)ethyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((6-methylpyridin-3-yl)methyl)quinazolin-4-amine,

4-(((6-(4-Fluorophenyl)-8-methoxyquinazolin-4-yl)amino)methyl)-1-methylpyridin-2(1H)-one,

N-((2-(Dimethylamino)pyrimidin-5-yl)methyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine,

N-((5-Chloropyrimidin-2-yl)methyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine,

5-(((6-(4-Fluorophenyl)-8-methoxyquinazolin-4-yl)amino)methyl)-N-methylpicolinamide,

6-(4-Fluorophenyl)-8-methoxy-N-((2-methylpyrimidin-5-yl)methyl)quinazolin-4-amine,,

N-(1-(3-Ethyl-1,2,4-oxadiazol-5-yl)ethyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-(1-(6-methoxypyridin-3-yl)ethyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-(1-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-(1-(6-methylpyridin-3-yl)ethyl)quinazolin-4-amine,

2-((6-(4-Fluorophenyl)-8-methoxyquinazolin-4-yl)amino)-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethan-1-ol,

6-(4-Fluorophenyl)-8-methoxy-N-(1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)quinazolin-4-amine,

N-(Cyclopropylmethyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-(1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((2-(trifluoromethyl)pyrimidin-5-yl)methyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-(1-(5-methyl-1,3,4-thiadiazol-2-yl)ethyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-N-(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)ethyl)-8-methoxyquinazolin-4-amine,

N-((6-(Dimethylamino)pyridin-3-yl)methyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-[[5-(trifluoromethyl)-3-pyridyl]methyl]quinazolin-4-amine,

3-((6-(4-Fluorophenyl)-8-methoxyquinazolin-4-yl)amino)tetrahydrothiophene 1,1-dioxide,

6-(4-Fluorophenyl)-8-methoxy-N-((tetrahydro-2H-pyran-4-yl)methyl)quinazolin-4-amine,

Single enantiomer 1 of 3-((6-(4-Fluorophenyl)-8-methoxyquinazolin-4-yl)amino)tetrahydrothiophene 1,1-dioxide,

Single enantiomer 2 of 3-((6-(4-Fluorophenyl)-8-methoxyquinazolin-4-yl)amino)tetrahydrothiophene 1,1-dioxide,

N-(5-(((6-(4-Fluorophenyl)-8-methoxyquinazolin-4-yl)amino)methyl)pyridin-2-yl)acetamide,

6-(4-Fluorophenyl)-8-methoxy-N-(2-(6-methylpyridin-3-yl)ethyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-(1-methylpiperidin-4-yl)quinazolin-4-amine,

N1-(6-(4-Fluorophenyl)-8-methoxyquinazolin-4-yl)-N3,N3-dimethylpropane-1,3-diamine,

(S)-2-((6-(4-Fluorophenyl)-8-methoxyquinazolin-4-yl)amino)-2-(6-methoxypyridin-3-yl)ethan-1-ol,

6-(4-Fluorophenyl)-8-methoxy-N-((6-morpholinopyridazin-3-yl)methyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((6-methoxypyridin-3-yl)methyl)quinazolin-4-amine,

N-(4-ethoxybenzyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-(2-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-[[2-(trifluoromethyl)-4-pyridyl]methyl]quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((1-methyl-1H-tetrazol-5-yl)methyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((1-methyl-1H-pyrazol-4-yl)methyl)quinazolin-4-amine,

4-(2-((6-(4-Fluorophenyl)-8-methoxyquinazolin-4-yl)amino)ethyl)morpholin-3-one,

6-(4-Fluorophenyl)-8-methoxy-N-((1-methyl-1H-1,2,4-triazol-5-yl)methyl)quinazolin-4-amine-,

6-(4-Fluorophenyl)-8-methoxy-N-((2-methyl-2H-tetrazol-5-yl)methyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-N-(imidazo[1,2-a]pyrimidin-6-ylmethyl)-8-methoxyquinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((6-(2,2,2-trifluoroethoxy)pyridazin-3-yl)methyl)quinazolin-4-amine,

N-((4-Ethyl-4H-1,2,4-triazol-3-yl)methyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine,

N-([1,2,4]Triazolo[4,3-a]pyrimidin-3-ylmethyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine,

3-(((6-(4-Fluorophenyl)-8-methoxyquinazolin-4-yl)amino)methyl)-6-methylpyridin-2(1H)-one,

6-(4-Fluorophenyl)-8-methoxy-N-((3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((3-(piperidin-1-ylmethyl)-1,2,4-oxadiazol-5-yl)methyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((1-methyl-1H-1,2,3-triazol-4-yl)methyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((6-(4-methylpiperazin-1-yl)pyridin-3-yl)methyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((4-(trifluoromethyl)pyridin-3-yl)methyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((2-(trifluoromethyl)pyridin-3-yl)methyl)quinazolin-4-amine,

N-((5,6-Dimethylpyridin-3-yl)methyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-[(1-methylimidazol-2-yl)methyl]quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-(2-phenylcyclopropyl)quinazolin-4-amine,

N-[(3-Chloro-4-pyridyl)methyl]-6-(4-fluorophenyl)-8-methoxy-quinazolin-4-amine,

2-(3-Chloro-4-pyridyl)-2-[[6-(4-fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]ethanol,

N-[(3S,4R)-4-Ethoxytetrahydrofuran-3-yl]-6-(4-fluorophenyl)-8-methoxy-quinazolin-4-amine,

N-[(1,1-Dioxothian-4-yl)methyl]-6-(4-fluorophenyl)-8-methoxy-quinazolin-4-amine,

4-[[6-(4-Fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]-1-methyl-piperidin-2-one,

6-[[[6-(4-Fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]methyl]-1H-pyridin-2-one,

3-[[[6-(4-Fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]methyl]-1,4-dihydro-1,2,4-triazol-5-one,

N-[[1-(4-Chlorophenyl)cyclopropyl]methyl]-6-(4-fluorophenyl)-8-methoxy-quinazolin-4-amine,

(5R)-5-[[[6-(4-Fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]methyl]pyrrolidin-2-one,

(1S)-2-[[6-(4-Fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]-1-phenyl-ethanol,

N'-[6-(4-Fluorophenyl)-8-methoxy-quinazolin-4-yl]-N,N-dimethyl-1-(4-pyridyl)ethane-1,2-diamine,

(2S)-2-[[6-(4-fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]-4-methyl-pentanamide,

6-(4-Fluorophenyl)-8-methoxy-N-(2H-tetrazol-5-ylmethyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-[(2-methylindazol-6-yl)methyl]quinazolin-4-amine,

N-[2-[4-(Dimethylamino)phenyl]ethyl]-6-(4-fluorophenyl)-8-methoxy-quinazolin-4-amine,

4-[[[6-(4-Fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]methyl]-N,N-dimethyl-benzenesulfonamide,

6-(4-Fluorophenyl)-8-methoxy-N-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl)quinazolin-4-amine,

N-[(1R,5S)-8-Benzyl-8-azabicyclo[3.2.1]octan-3-yl]-6-(4-fluorophenyl)-8-methoxy-quinazolin-4-amine,

N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-6-(4-fluorophenyl)-8-methoxy-quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-(3-pyrrolidin-1-ylpropyl)quinazolin-4-amine,

(1S,2R)-1-[[6-(4-Fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]indan-2-ol,

6-(4-Fluorophenyl)-8-methoxy-N-[(4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)methyl]quinazolin-4-amine,

N-[(6-Chloroimidazo[1,2-a]pyridin-2-yl)methyl]-6-(4-fluorophenyl)-8-methoxy-quinazolin-4-amine,

N-[(4-Benzyloxyphenyl)methyl]-6-(4-fluorophenyl)-8-methoxy-quinazolin-4-amine,

N-[(1-Benzylazetidin-3-yl)methyl]-6-(4-fluorophenyl)-8-methoxy-quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-[[(2R)-tetrahydrofuran-2-yl]methyl]quinazolin-4-amine,

N-[Cyclohexyl(phenyl)methyl]-6-(4-fluorophenyl)-8-methoxy-quinazolin-4-amine,

3-(3-Chlorophenyl)-3-[[6-(4-fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]propan-1-ol,

6-(4-Fluorophenyl)-8-methoxy-N-[(1-methylbenzimidazol-5-yl)methyl]quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-[2-(4-methylpiperazin-1-yl)-1-phenyl-ethyl]quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-[(1S)-1-methyl-2-pyrrolidin-1-yl-ethyl]quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-[(1-methylindazol-7-yl)methyl]quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-[(1-methylazetidin-3-yl)methyl]quinazolin-4-amine,

(1R,2S)-1-[[6-(4-Fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]indan-2-ol,

3-[[6-(4-Fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]-1-methyl-pyrrolidin-2-one,

6-(4-Fluorophenyl)-8-methoxy-N-(1-tetrahydropyran-4-ylethyl)quinazolin-4-amine,

N-[[3-Chloro-5-(trifluoromethyl)-2-pyridyl]methyl]-6-(4-fluorophenyl)-8-methoxy-quinazolin-4-amine,

1-[4-[[[6-(4-Fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]methyl]-1-piperidyl]ethanone,

2,2-Difluoro-3-[[6-(4-fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]propan-1-ol,

6-(4-Fluorophenyl)-8-methoxy-N-(2-piperazin-1-ylethyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-(pyrrolidin-3-ylmethyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-(pyrrolidin-2-ylmethyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-(1-methyl-2-morpholino-ethyl)quinazolin-4-amine,

(S)-6-(4-Fluorophenyl)-8-methoxy-N-((tetrahydrofuran-2-yl)methyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((1-methylpyrrolidin-3-yl)methyl)quinazolin-4-amine,

N1,N1-Diethyl-N3-(6-(4-fluorophenyl)-8-methoxyquinazolin-4-yl)propane-1,3-diamine,

(R)-6-(4-Fluorophenyl)-8-methoxy-N-(1-methylpiperidin-3-yl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-((1-methylpiperidin-2-yl)methyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-(2-(1-methylazetidin-3-yl)ethyl)quinazolin-4-amine,

2-[[6-(4-Fluorophenyl)-8-methoxy-quinazolin-4-yl]amino]-2-tetrahydropyran-4-yl-ethanol formate-,

6-(4-Fluorophenyl)-8-methoxy-N-[(1-methyl-4-piperidyl)methyl]quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-[(1-methylindazol-4-yl)methyl]quinazolin-4-amine,

(R)-5-(1-((6-(4-fluorophenyl)-8-methoxyquinazolin-4-yl)amino)ethyl)-2-(trifluoromethyl)pyridine 1-oxide formate,

6-(4-fluorophenyl)-8-methoxy-N-(2-morpholinoethyl)quinazolin-4-amine,

N-(((1r,4r)-4-Aminocyclohexyl)methyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine-,

8-Methoxy-6-(5-methyl-1,3,4-thiadiazol-2-yl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine-,

8-Methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(5-methylpyridin-2-yl)quinazolin-4-amine,

6-(8-Methoxy-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-6-yl)nicotinonitrile,

6-(5-(Difluoromethyl)pyridin-2-yl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

6-(8-Methoxy-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-6-yl)pyridin-3-ol,

6-(5-(Difluoromethoxy)pyridin-2-yl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

8-Methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(5-(methylsulfonyl)pyridin-2-yl)quinazolin-4-amine,

6-(8-Methoxy-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-6-yl)nicotinamide,

6-(8-Methoxy-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-6-yl)-N-methylnicotinamide,

8-Methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(5-(trifluoromethoxy)pyridin-2-yl)quinazolin-4-amine,

6-[5-(Dimethylamino)-2-pyridyl]-8-methoxy-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

6-(5-Cyclopropylpyridin-2-yl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

6-(5-Chloropyridin-2-yl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

8-Methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(6-methylpyridin-3-yl)quinazolin-4-amine,

8-Methoxy-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

8-Methoxy-6-(1-methyl-1H-pyrazol-3-yl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

6-(1,5-Dimethyl-1H-pyrazol-3-yl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

8-Methoxy-6-(6-methoxypyridazin-3-yl)-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

8-Methoxy-6-(6-methylpyridazin-3-yl)-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

8-Methoxy-N-[(6-methylpyridazin-3-yl)methyl]-6-(5-methylpyrimidin-2-yl)quinazolin-4-amine,

6-(5-Fluoro-2-pyridyl)-8-methoxy-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

6-(5-Fluoropyrimidin-2-yl)-8-methoxy-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

6-[8-Methoxy-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-6-yl]pyridazin-3-ol,

8-Methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(5-(trifluoromethyl)pyridin-2-yl)quinazolin-4-amine,

8-Methoxy-6-(5-methoxypyridin-2-yl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

8-Methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(5-methylthiazol-2-yl)quinazolin-4-amine-,

8-Methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(4-(trifluoromethyl)thiazol-2-yl)quinazolin-4-amine,

6-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

8-Methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(4-methylthiazol-2-yl)quinazolin-4-amine,

8-Methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(2-methylthiazol-5-yl)quinazolin-4-amine,

(R)-5-(1-((8-Methoxy-6-(5-methyl-1,3,4-thiadiazol-2-yl)quinazolin-4-yl)amino)ethyl)-2-(trifluoromethyl)pyridine 1-oxide,

(R)-8-Methoxy-6-(5-methyl-1,3,4-thiadiazol-2-yl)-N-(1-(6-methylpyridazin-3-yl)ethyl)quinazolin-4-amine,

(R)-8-Methoxy-6-(5-methyl-1,3,4-thiadiazol-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine-,

8-Methoxy-6-(5-methylpyrimidin-2-yl)-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]quinazolin-4-amine,

6-(5-Fluoropyrimidin-2-yl)-8-methoxy-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]quinazolin-4-amine,

6-(5-Fluoro-2-pyridyl)-8-methoxy-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]quinazolin-4-amine,

8-Methoxy-N-[(1R)-1-(6-methylpyridazin-3-yl)ethyl]-6-(5-methylpyrimidin-2-yl)quinazolin-4-amine,

8-Methoxy-6-(1-methylpyrazol-3-yl)-N-[(1R)-1-(6-methylpyridazin-3-yl)ethyl]quinazolin-4-amine,

6-[5-(Difluoromethyl)-2-pyridyl]-8-methoxy-N-[(1R)-1-(6-methylpyridazin-3-yl)ethyl]quinazolin-4-amine,

8-Methoxy-N-[(1R)-1-(6-methylpyridazin-3-yl)ethyl]-6-(5-methyl-2-pyridyl)quinazolin-4-amine,

6-(5-Fluoro-2-pyridyl)-8-methoxy-N-[(1R)-1-(6-methylpyridazin-3-yl)ethyl]quinazolin-4-amine,

8-Methoxy-6-(3-methylisothiazol-5-yl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

(R)-8-methoxy-6-(5-methylpyridin-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

(R)-8-methoxy-6-(5-methylthiazol-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

(R)-8-methoxy-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-6-ol,

(R)-8-methoxy-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

8-Methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(5-(trifluoromethyl)thiazol-2-yl)quinazolin-4-amine,

8-Methoxy-6-(1-methyl-1H-pyrazol-4-yl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

6-(4,5-Dimethylthiazol-2-yl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

6-(4-Fluoro-3-methylphenyl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

6-(2,4-Difluorophenyl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

6-(4-Fluoro-3-methoxyphenyl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

6-(4-Fluoro-2-methylphenyl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

6-(4-Fluoro-2-(trifluoromethyl)phenyl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

6-(3-Fluorophenyl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

6-(2,4-Difluorophenyl)-8-methoxy-N-[(1R)-1-(6-methylpyridazin-3-yl)ethyl]quinazolin-4-amine,

6-[4-[(Dimethylamino)methyl]phenyl]-8-methoxy-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine formate,

4-[8-Methoxy-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-6-yl]-N,N-dimethyl-benzamide,

6-[4-(Dimethylamino)phenyl]-8-methoxy-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

8-Methoxy-6-(4-methoxyphenyl)-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

Single enantiomer 1 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine,

Single enantiomer 2 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine,6-(3,4-Difluorophenyl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

6-(4-Fluoro-2-methoxyphenyl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine-,

8-Methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(2,4,6-trifluorophenyl)quinazolin-4-amine,

2-(8-Methoxy-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-6-yl)-5-methylbenzonitrile,

5-Fluoro-2-(8-methoxy-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-6-yl)benzonitrile,

5-Fluoro-2-(8-methoxy-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-6-yl)phenol,

(R)-6-(4-fluorophenyl)-8-methoxy-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

6-(4-fluorophenyl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

(R)-6-(4-Fluorophenyl)-8-methoxy-2-methyl-N-(1-(2-(trifluoromethyl)pyrimidin-5 yl)ethyl)quinazolin-4-amine-,

(R)-6-(4-Fluorophenyl)-8-methoxy 4-((1-(2 (trifluoromethyl)pyrimidin-5 yl)ethyl)-amino)-quinazolin-2-ol ,

6-(4-fluorophenyl)-8-iodo-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

6-(4-fluorophenyl)-N-((6-methylpyridazin-3-yl)methyl)-8-(methylsulfonyl)quinazolin-4-amine,

(R)-N-(6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)methanesulfonamide,

N-(6-(4-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-8-yl)methanesulfonamide,

(R)-6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazoline-8-sulfonamide,

(R)-6-(4-fluorophenyl)-8-(1-methyl-1H-pyrazol-4-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine-,

(R)-6-(4-Fluorophenyl)-8-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

(R)-6-(4-Fluorophenyl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)-8-(1,3,5-trimethyl-1H-pyrazol-4-yl)quinazolin-4-amine,

(R)-6-(4-Fluorophenyl)-8-(pyridin-4-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

(R)-4-(6-(4-Fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)-N,N-dimethylbenzamide,

(R)-6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)-quinazolin-8-ol ,

6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-ol,

((R)-8-methoxy-6-(3-methyl-1H-pyrazol-1-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

(R)-8-methoxy-6-(5-methyl-1H-pyrazol-1-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

(R)-8-Methoxy-6-(4-methyl-1H-imidazol-1-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine-,

(R)-8-methoxy-6-(5-methyl-1H-imidazol-1-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine-,

(R)-8-Methoxy-6-(4-methyl-1H-pyrazol-1-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine-,

Single enantiomer 1 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine,

Single enantiomer 2 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine-,

Single enantiomer 1 6-(4-fluorophenyl)-8-methoxy-N-(1-(6-methylpyridin-3-yl)ethyl)quinazolin-4-amine,

Single enantiomer 2 6-(4-fluorophenyl)-8-methoxy-N-(1-(6-methylpyridin-3-yl)ethyl)quinazolin-4-amine-,

Single enantiomer 1 6-(4-fluorophenyl)-8-methoxy-N-(1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)quinazolin-4-amine,

Single enantiomer 2 6-(4-fluorophenyl)-8-methoxy-N-(1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)quinazolin-4-amine,

Single enantiomer 1 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl)quinazolin-4-amine,

Single enantiomer 2 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl)quinazolin-4-amine,

Single enantiomer 1 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(6-methoxypyridin-3-yl)ethyl)quinazolin-4-amine,

Single enantiomer 2 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(6-methoxypyridin-3-yl)ethyl)quinazolin-4-amine-,

Single enantiomer 1 of 2-((6-(4-fluorophenyl)-8-methoxyquinazolin-4-yl)amino)-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethan-1-ol,

Single enantiomer 2 of 2-((6-(4-fluorophenyl)-8-methoxyquinazolin-4-yl)amino)-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethan-1-ol-,

Single enantiomer 1 of N-(1-(3-ethyl-1,2,4-oxadiazol-5-yl)ethyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine,

Single enantiomer 2 of N-(1-(3-ethyl-1,2,4-oxadiazol-5-yl)ethyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine-,

Single enantiomer 1 of N-(1-cyclopropylethyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine,

Single enantiomer 2 of N-(1-cyclopropylethyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine,

Single enantiomer –of N3-(6-(4-fluorophenyl)-8-methoxyquinazolin-4-yl)-N1,N1-dimethylbutane-1,3-diamine,

Single enantiomer 2 of N3-(6-(4-fluorophenyl)-8-methoxyquinazolin-4-yl)-N1,N1-dimethylbutane-1,3-diamine-,

Single enantiomer 1 of 6-(4-fluorophenyl)-N-[1-(3-isopropyl-1,2,4-oxadiazol-5-yl)ethyl]-8-methoxy-quinazolin-4-amine-,

Single enantiomer 2 of 6-(4-fluorophenyl)-N-[1-(3-isopropyl-1,2,4-oxadiazol-5-yl)ethyl]-8-methoxy-quinazolin-4-amine-,

Single enantiomer 1 of 6-(4-fluorophenyl)-8-methoxy-N-[2-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]quinazolin-4-amine,

Single enantiomer 2 of 6-(4-fluorophenyl)-8-methoxy-N-[2-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]quinazolin-4-amine,

Single enantiomer 1 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(5-methyl-1,3,4-thiadiazol-2-yl)ethyl)quinazolin-4-amine,

Single enantiomer 2 of 6-(4-fluorophenyl)-8-methoxy-N-(1-(5-methyl-1,3,4-thiadiazol-2-yl)ethyl)quinazolin-4-amine,

(R)-6-(4-Fluorophenyl)-8-iodo-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,-

(R)-6-(4-fluorophenyl)-8-(methylsulfonyl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

6-(4-Fluorophenyl)-8-methoxy-N-(1-(3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine,

6-(4-fluorophenyl)-8-methoxy-N-(2-(3-methyl-1,2,4-oxadiazol-5-yl)propan-2-yl)quinazolin-4-amine,

(rac)-N-(1-(4H-1,2,4-triazol-3-yl)ethyl)-6-(4-fluorophenyl)-8-methoxyquinazolin-4-amine,

(S)-6-(4-fluorophenyl)-8-methoxy-N-(1-(5-methyl-4H-1,2,4-triazol-3-yl)ethyl)quinazolin-4-amine,

6-(3,5-Difluoropyridin-2-yl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine,

6-(3-Fluoro-5-methyl-2-pyridyl)-8-methoxy-*N*-[(6-methylpyridazin-3-yl)methyl] quinazolin-4-amine,

6-(5-Ethylthiazol-2-yl)-8-methoxy-*N*-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,(R)-8-methoxy-6-(1-methyl-1H-1,2,4-triazol-3-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,(R)-8-methoxy-6-(1-methyl-1H-pyrazol-3-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine,

(R)-8-methoxy-6-(1-methyl-1H-1,2,4-triazol-3-yl)-N-(1-(6-methylpyridazin-3-yl)ethyl)quinazolin-4-amine,

(R)-6-(5-fluoropyridin-2-yl)-8-methoxy-N-(1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)quinazolin-4-amine,

(R)-8-methoxy-N-(1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)-6-(5-methylpyridin-2-yl)quinazolin-4-amine,

8-Methoxy-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-6-(5-methyl-2-pyridyl)quinazolin-4-amine,

6-(5-fluoro-2-pyridyl)-8-methoxy-N-[(1R)-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]quinazolin-4-amine,

8-methoxy-N-[(1R)-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-(5-methyl-2-pyridyl)quinazolin-4-amine,

2-((8-methoxy-6-(5-methylpyrimidin-2-yl)quinazolin-4-yl)amino)-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethan-1-ol,

6-(5-fluoro-2-pyridyl)-8-methoxy-N-[1-[6-(trifluoromethyl)pyridazin-3-yl]ethyl]quinazolin-4-amine,

6-(5-fluoropyridin-2-yl)-8-methoxy-N-(1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl)quinazolin-4-amine,


6-(5-fluoropyridin-2-yl)-8-methoxy-N-(1-(5-methyl-1,3,4-thiadiazol-2-yl)ethyl)quinazolin-4-amine,

8-methoxy-N-[(1R)-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-(5-methylpyrimidin-2-yl)quinazolin-4-amine,

(S)-6-(5-fluoropyridin-2-yl)-8-methoxy-N-(1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)quinazolin-4-amine~~.~~ and

8-Methoxy-N-[(1S)-1-(6-methylpyridazin-3-yl)ethyl]-6-(5-methylpyrimidin-2-yl)quinazolin-4-amine.

~~8~~7. A compound of formula (I) according to claim 1, wherein Y is -OR^D, represented by formula (Ia)



(Ia)

wherein

Z is selected from the group consisting of aryl,

wherein any of such aryl may be optionally substituted by one or more groups selected from halo;

R_1 is H,

R_2 is selected from the group consisting of heteroaryl(C_1-C_4)alkyl-,

wherein any of such heteroaryl may be optionally substituted by one or more groups selected from (C_1-C_3)alkyl, C_1-C_6)haloalkyl;

R^A and R^B are at each occurrence independently H or selected from the group consisting of (C_1-C_4)alkyl-;

R^C is at each occurrence H or selected from the group consisting of (C_1-C_6)alkyl;

R^D is selected in the group consisting of H, (C_1-C_6)alkyl, (C_3-C_8)heterocycloalkyl-(C_1-C_6)alkyl-, R^COC(O)(C_1-C_4)alkylene-, (R^AR^B)N(C_1-C_6)alkylene-, (C_3-C_8)heterocycloalkyl, R^CO(C1-C4)alkylene-, (R^AR^B)N(O)C(C_1-C_4)alkylene-, (C_3-C_8)cycloalkyl-(C_1-C_6)alkyl-,

wherein any of such ~~heterocycloalkly~~ heterocycloalkyl may be optionally substituted by one or more groups selected from (C_1-C_3)alkyl;

J is H.

~~9~~8. A compound of formula I according to claim ~~4~~1, selected from:

(R)-6-(4-Fluorophenyl)-8-((tetrahydro-2H-pyran-4-yl)oxy)-N-(1-(2-(trifluoromethyl) pyrimidin-5-yl)ethyl)quinazolin-4-amine,

6-(4-fluorophenyl)-8-{[(3R)-oxolan-3-yl]oxy}-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}quinazolin-4-amine,

~~(R)-4-(2-(1,1-dioxidothiomorpholino)ethyl)-8-(4-fluorophenyl)-3-oxo-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide,~~

6-(4-fluorophenyl)-8-isopropoxy-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

8-(cyclopropylmethoxy)-6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

2-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxyethanol,

2-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxy-N,N-dimethyl-acetamide,

6-(4-fluorophenyl)-8-(2-methoxyethoxy)-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-(oxetan-3-ylmethoxy)quinazolin-4-amine,

6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-tetrahydropyran-4-yloxy-quinazolin-4-amine,

6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-(2-morpholinoethoxy)quinazolin-4-amine,

6-(4-fluorophenyl)-8-[(1-methyl-4-piperidyl)oxy]-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

8-[3-(dimethylamino)propoxy]-6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

ethyl 2-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxyacetate,

8-ethoxy-6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

2-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxyacetic acid, sodium salt,

8-(azetidin-3-ylmethoxy)-6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-pyrrolidin-3-yloxy-quinazolin-4-amine,

6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-(morpholin-2-ylmethoxy)quinazolin-4-amine,

8-(azetidin-3-yloxy)-6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-(4-piperidyloxy)quinazolin-4-amine,

6-(4-fluorophenyl)-8-[(1-methylazetidin-3-yl)methoxy]-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

6-(4-fluorophenyl)-8-[(4-methylmorpholin-2-yl)methoxy]-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine,

6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-(1-methylpyrrolidin-3-yl)oxy-quinazolin-4-amine,

(R)-2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)acetamide,

(*R*)-2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)-1-(pyrrolidin-1-yl)ethan-1-one,

(*R*)-*N*,*N*-diethyl-2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)acetamide,

6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-[(3S)-pyrrolidin-3-yl]oxy-quinazolin-4-amine, and


6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-[(3R)-pyrrolidin-3-yl]oxy-quinazolin-4-amine.

10 9. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 9 8, or a pharmaceutically acceptable salt thereof, either alone or in combination with another one or more active ingredient, in admixture with one or more pharmaceutically acceptable carrier or excipient.

11 10. The pharmaceutical composition according to claim 10 9, wherein the pharmaceutical composition is to be administered for orally administration.

~~12~~11. A compound according to any one of claims 1 to ~~9~~ 8 or a pharmaceutical composition according to claim~~s~~ ~~10~~ 9 or~~and~~ ~~11~~ 10 for use as a medicament.

~~13~~12. Use of a~~A~~ compound of formula (I)



(I)

wherein

Z is selected from the group consisting of $(C_3$-$C_8)$heterocycloalkyl, (R^AR^B)N-, heteroaryl and aryl,

wherein any of such heteroaryl, heterocycloalkyl and aryl may be optionally substituted by one or more groups selected from $(C_1$-$C_3)$alkyl-, halo, CN, (R^AR^B)NC(O)-, $(C_1$-$C_6)$haloalkyl-, R^AO-, $(R^AR^B)N(C_1$-$C_6)$alkylene-, $(C_3$-$C_7)$cycloalkyl-, R^CSO_2- and (R^AR^B)N-;

R_1 is H or $(C_1$-$C_4)$alkyl;

R_2 is selected from the group consisting of $(C_1$-$C_6)$alkyl-, heteroaryl$(C_1$-$C_4)$alkyl-, $(C_3$-$C_8)$heterocycloalkyl-$(C_1$-$C_6)$alkyl-, heteroaryl-$(C_1$-$C_6)$hydroxyalkyl-, $(C_3$-$C_8)$heterocycloalkyl, $(C_3$-$C_8)$cycloalkyl-$(C_1$-$C_6)$alkyl-, aryl-$(C_1$-$C_4)$alkyl-, $(R^AR^B)N(C_1$-$C_6)$alkylene-, $(R^AR^B)N(O)C(C_1$-$C_4)$alkylene- and $R^AO(C_1$-$C_4)$alkylene-

wherein any of such alkyl, alkylene, aryl, heteroaryl and heterocycloalkyl may be optionally substituted by one or more groups selected from $(C_1$-$C_3)$alkyl, $R^AO(C_1$-$C_4)$alkylene-, $(C_1$-$C_6)$haloalkyl, halo, oxo, R^AO-, $(C_3$-$C_8)$heterocycloalkyl-$(C_1$-$C_6)$alkyl-, heteroaryl, $(R^AR^B)N$-, -$NHC(O)R^C$, -$C(O)N(R^AR^B)$, -$SO_2N(R^AR^B)$, -$O(C_1$-$C_4)$alkylene-$N(R^AR^B)$ and aryl optionally substituted by halo, -OR^C, aryl-$(C_1$-$C_4)$alkyl- and -$C(O)R^A$;

R^A and R^B are at each occurrence independently H or selected from the group consisting of $(C_1$-$C_4)$alkyl-, $(C_3$-$C_8)$cycloalkyl- and $(C_1$-$C_6)$ haloalkyl, or

R^A and R^B may form together with the nitrogen atom to which they are attached a 5- or 6-membered saturated heterocyclic monocyclic ring system optionally containing a further heteroatom which is nitrogen or oxygen, which may be optionally substituted by one or more groups selected from $(C_1$-$C_4)$alkyl and oxo;

R^C is at each occurrence H or selected from the group consisting of $(C_1$-$C_6)$alkyl, $(R^AR^B)N$- and aryl-$(C_1$-$C_4)$alkyl-;

Y is selected from the group consisting of H, -OR^D, R^CSO_2, halo, -$NHSO_2R^C$, heteroaryl and $(C_3$-$C_8)$heterocycloalkyl,

wherein any of such heteroaryl and heterocycloalkyl may be optionally substituted by one or more groups selected from $(C_1$-$C_3)$alkyl and -$C(O)N(R^AR^B)$;

R^D is selected from the group consisting of H, $(C_1$-$C_6)$alkyl, $(C_3$-$C_8)$heterocycloalkyl-$(C_1$-$C_6)$alkyl-, $R^COC(O)(C_1$-$C_4)$alkylene-, $(R^AR^B)N(C_1$-$C_6)$alkylene-, $(C_3$-$C_8)$heterocycloalkyl, $(C_3$-$C_8)$cycloalkyl-$(C_1$-$C_6)$alkyl-, $R^CO(C1$-$C4)$alkylene- and $(R^AR^B)N(O)C(C_1$-$C_4)$alkylene-,

wherein any of such heterocycloalkyl may be optionally substituted by one or more groups selected from $(C_1$-$C_3)$alkyl-;


J is H or selected from the group consisting of (C_1-C_6)alkyl, (R^AR^B)N-, (C_1-C_6)haloalkyl, -OR^C and halo,

~~according to any one of claims 1 to 9 or a pharmaceutical composition according to claims 10 and 11 for the use~~ in the manufacture of a medicament for treatment of any disease wherein the $P2X_3$ receptors are involved~~.~~

~~14. A compound according to any one of claims 1 to 9 or a pharmaceutical composition according to claims 10 and 11 for use in the prevention and/or treatment of~~ selected from respiratory diseases including cough, sub-acute or chronic cough, treatment-resistant cough, idiopathic chronic cough, post-viral cough, iatrogenic cough, asthma, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and cough associated with respiratory diseases such as COPD, asthma and bronchospasm.

~~15~~13. The use~~A compound or a pharmaceutical composition~~ according to claim ~~14~~ 12~~for use~~, wherein the respiratory disease is ~~in the treatment of~~ chronic cough.

~~16~~14. A compound of formula Ib



(Ib)

wherein

R_3 is OH or halo,

R_4 is H or OH,

R_5 is ~~halo or~~ -OMe,

R_6 is ~~halo or~~ Z,

Z is as defined ~~above~~in claim 1.

~~17~~15. Use of compounds of formula (Ib) according to claim ~~16~~14, as intermediates in the preparation of compounds of formula (I) as described in claim 1.